First Time Loading...
C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.39 AUD Market Closed
Updated: May 29, 2024

Gross Margin
Cyclopharm Ltd

63.1%
Current
70%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.1%
=
Gross Profit
17.5m
/
Revenue
27.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
AU
Cyclopharm Ltd
ASX:CYC
130.8m AUD
63%
US
Abbott Laboratories
NYSE:ABT
177.4B USD
55%
US
Intuitive Surgical Inc
NASDAQ:ISRG
142.2B USD
66%
US
Stryker Corp
NYSE:SYK
129.2B USD
64%
US
Boston Scientific Corp
NYSE:BSX
110.5B USD
69%
IE
Medtronic PLC
NYSE:MDT
107.5B USD
66%
US
Becton Dickinson and Co
NYSE:BDX
65.9B USD
41%
DE
Siemens Healthineers AG
XETRA:SHL
60.2B EUR
38%
US
Edwards Lifesciences Corp
NYSE:EW
52.4B USD
77%
US
Dexcom Inc
NASDAQ:DXCM
50.5B USD
63%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
365.6B CNY
65%
C
Cyclopharm Ltd
ASX:CYC
Country AU
Market Cap 130.8m AUD
Gross Margin
63%
Abbott Laboratories
NYSE:ABT
Country US
Market Cap 177.4B USD
Gross Margin
55%
Intuitive Surgical Inc
NASDAQ:ISRG
Country US
Market Cap 142.2B USD
Gross Margin
66%
Stryker Corp
NYSE:SYK
Country US
Market Cap 129.2B USD
Gross Margin
64%
Boston Scientific Corp
NYSE:BSX
Country US
Market Cap 110.5B USD
Gross Margin
69%
Medtronic PLC
NYSE:MDT
Country IE
Market Cap 107.5B USD
Gross Margin
66%
Becton Dickinson and Co
NYSE:BDX
Country US
Market Cap 65.9B USD
Gross Margin
41%
Siemens Healthineers AG
XETRA:SHL
Country DE
Market Cap 60.2B EUR
Gross Margin
38%
Edwards Lifesciences Corp
NYSE:EW
Country US
Market Cap 52.4B USD
Gross Margin
77%
Dexcom Inc
NASDAQ:DXCM
Country US
Market Cap 50.5B USD
Gross Margin
63%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Country CN
Market Cap 365.6B CNY
Gross Margin
65%

Profitability Report

View the profitability report to see the full profitability analysis for Cyclopharm Ltd.

Full Profitability Report

See Also

Summary
CYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYC stock valuation using valuation multiples.
Wall Street Estimates
CYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.1%
=
Gross Profit
17.5m
/
Revenue
27.8m
What is the Gross Margin of Cyclopharm Ltd?

Based on Cyclopharm Ltd's most recent financial statements, the company has Gross Margin of 63.1%.

ALPHA SPREAD
Join more than 141,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.